Abstract: The present disclosure relates to a composition for treating diabetic retinopathy, containing scAAV2-shmTOR-SD (CRG-01), a therapeutic method of suppressing expression of mTOR proteins to treat diabetic retinopathy, and a method of using an RNAi method by means of short hairpin RNA (shRNA) as a method of suppressing expression and activity of mTOR proteins, and development of a composition for treating diabetic retinopathy by performing delivery to retina using AAV2 and being expressed in the form of mTOR shRNA as a method for expressing mTOR shRNA in cells of the retina.